| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 30,485 | - |
| Selling, general and administrative | 27,103 | - |
| Research and development | 6,335 | - |
| Cost of revenue | 2,040 | - |
| Other segment items | 4,819 | - |
| Net loss | -9,812 | - |
| Depreciation expense | - | 100 |
| Stock-based compensation | 2,632 | 1,914 |
| Depreciation expense | 119 | 96 |
| Non-cash interest expense | 2,075 | 1,359 |
| Loss on disposal of fixed assets | -246 | -178 |
| Net loss | - | -9,538 |
| Loss on termination of financing lease | -3 | -4 |
| Amortization of operating lease right-of-use asset | 220 | 146 |
| Amortization of finance lease right-of-use asset | 252 | 165 |
| Non-cash accretion of r&d funding liability | 375 | - |
| Change in fair value of derivative liability | 886 | 852 |
| Prepaid expenses and other assets | 1,276 | -818 |
| Collaboration receivable, billed and unbilled | 253 | 8,149 |
| Inventory | -159 | 59 |
| Accounts payable | -311 | 425 |
| Deferred revenue | 1,564 | 481 |
| Accounts receivable | 6,999 | 9,145 |
| Accrued expenses and other current liabilities | -911 | -410 |
| Operating lease liability | -233 | -154 |
| Net cash used in operating activities | -13,036 | -22,721 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from exercise of stock options | 0 | 0 |
| Payment of debt amendment fees | 0 | 0 |
| Repayment of debt | 11,919 | 8,029 |
| Repayment of finance lease | 277 | 183 |
| Payment of equity issuance costs | 0 | - |
| Net cash used in financing activities | -12,196 | -8,212 |
| Net decrease in cash and cash equivalents | -25,232 | -30,933 |
| Cash and cash equivalents at beginning of period | 46,329 | - |
| Cash and cash equivalents at end of period | 21,097 | - |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)